vs
ALLIENT INC（ALNT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是ALLIENT INC的1.4倍（$207.3M vs $143.4M），ALLIENT INC净利率更高（4.5% vs -62.0%，领先66.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 17.5%），ALLIENT INC自由现金流更多（$11.7M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -1.2%）
Allient Inc是一家全球化技术制造企业，主营精密运动、控制及电源解决方案的设计、生产与分销，核心服务航空航天、国防、医疗设备、工业自动化、商用出行等领域，业务覆盖北美、欧洲及亚太地区。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ALNT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $143.4M | $207.3M |
| 净利润 | $6.4M | $-128.6M |
| 毛利率 | 32.4% | — |
| 营业利润率 | 7.9% | -54.7% |
| 净利率 | 4.5% | -62.0% |
| 营收同比 | 17.5% | 25.9% |
| 净利润同比 | 111.8% | 3.5% |
| 每股收益（稀释后） | $0.38 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $143.4M | $207.3M | ||
| Q3 25 | $138.7M | $159.9M | ||
| Q2 25 | $139.6M | $166.5M | ||
| Q1 25 | $132.8M | $139.3M | ||
| Q4 24 | $122.0M | $164.6M | ||
| Q3 24 | $125.2M | $139.5M | ||
| Q2 24 | $136.0M | $147.0M | ||
| Q1 24 | $146.7M | $108.8M |
| Q4 25 | $6.4M | $-128.6M | ||
| Q3 25 | $6.5M | $-180.4M | ||
| Q2 25 | $5.6M | $-115.0M | ||
| Q1 25 | $3.6M | $-151.1M | ||
| Q4 24 | $3.0M | $-133.2M | ||
| Q3 24 | $2.1M | $-133.5M | ||
| Q2 24 | $1.1M | $-131.6M | ||
| Q1 24 | $6.9M | $-170.7M |
| Q4 25 | 32.4% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 33.2% | — | ||
| Q1 25 | 32.2% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 31.4% | — | ||
| Q2 24 | 29.9% | — | ||
| Q1 24 | 32.3% | — |
| Q4 25 | 7.9% | -54.7% | ||
| Q3 25 | 8.8% | -106.9% | ||
| Q2 25 | 8.4% | -64.8% | ||
| Q1 25 | 6.6% | -102.6% | ||
| Q4 24 | 5.3% | -74.3% | ||
| Q3 24 | 5.3% | -94.6% | ||
| Q2 24 | 3.6% | -79.1% | ||
| Q1 24 | 8.2% | -151.9% |
| Q4 25 | 4.5% | -62.0% | ||
| Q3 25 | 4.7% | -112.8% | ||
| Q2 25 | 4.0% | -69.0% | ||
| Q1 25 | 2.7% | -108.5% | ||
| Q4 24 | 2.5% | -80.9% | ||
| Q3 24 | 1.7% | -95.7% | ||
| Q2 24 | 0.8% | -89.5% | ||
| Q1 24 | 4.7% | -156.8% |
| Q4 25 | $0.38 | $-1.28 | ||
| Q3 25 | $0.39 | $-1.81 | ||
| Q2 25 | $0.34 | $-1.17 | ||
| Q1 25 | $0.21 | $-1.57 | ||
| Q4 24 | $0.17 | $-1.34 | ||
| Q3 24 | $0.13 | $-1.40 | ||
| Q2 24 | $0.07 | $-1.52 | ||
| Q1 24 | $0.42 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.7M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $301.5M | $-80.0M |
| 总资产 | $577.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $40.7M | $421.0M | ||
| Q3 25 | $39.5M | $202.5M | ||
| Q2 25 | $49.9M | $176.3M | ||
| Q1 25 | $47.8M | $127.1M | ||
| Q4 24 | $36.1M | $174.0M | ||
| Q3 24 | $37.1M | $150.6M | ||
| Q2 24 | $31.3M | $480.7M | ||
| Q1 24 | $31.5M | $112.3M |
| Q4 25 | $301.5M | $-80.0M | ||
| Q3 25 | $294.2M | $9.2M | ||
| Q2 25 | $289.1M | $151.3M | ||
| Q1 25 | $272.8M | $144.2M | ||
| Q4 24 | $264.9M | $255.0M | ||
| Q3 24 | $272.9M | $346.8M | ||
| Q2 24 | $265.7M | $432.4M | ||
| Q1 24 | $267.1M | $140.3M |
| Q4 25 | $577.6M | $1.5B | ||
| Q3 25 | $585.1M | $1.2B | ||
| Q2 25 | $588.1M | $1.3B | ||
| Q1 25 | $586.9M | $1.3B | ||
| Q4 24 | $575.8M | $1.5B | ||
| Q3 24 | $596.4M | $1.5B | ||
| Q2 24 | $595.8M | $1.6B | ||
| Q1 24 | $611.6M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $11.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 8.1% | -48.6% |
| 资本支出强度资本支出/营收 | 1.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.12× | — |
| 过去12个月自由现金流最近4个季度 | $49.7M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $13.6M | $-99.8M | ||
| Q3 25 | $4.7M | $-91.4M | ||
| Q2 25 | $24.5M | $-108.3M | ||
| Q1 25 | $13.9M | $-166.5M | ||
| Q4 24 | $12.4M | $-79.3M | ||
| Q3 24 | $12.1M | $-67.0M | ||
| Q2 24 | $8.2M | $-77.0M | ||
| Q1 24 | $9.2M | $-190.7M |
| Q4 25 | $11.7M | $-100.8M | ||
| Q3 25 | $2.8M | $-92.7M | ||
| Q2 25 | $22.4M | $-110.7M | ||
| Q1 25 | $12.9M | $-167.8M | ||
| Q4 24 | $9.6M | $-79.5M | ||
| Q3 24 | $10.5M | $-68.6M | ||
| Q2 24 | $5.8M | $-79.0M | ||
| Q1 24 | $6.2M | $-193.9M |
| Q4 25 | 8.1% | -48.6% | ||
| Q3 25 | 2.0% | -58.0% | ||
| Q2 25 | 16.0% | -66.5% | ||
| Q1 25 | 9.7% | -120.5% | ||
| Q4 24 | 7.9% | -48.3% | ||
| Q3 24 | 8.4% | -49.2% | ||
| Q2 24 | 4.3% | -53.7% | ||
| Q1 24 | 4.2% | -178.2% |
| Q4 25 | 1.3% | 0.5% | ||
| Q3 25 | 1.4% | 0.8% | ||
| Q2 25 | 1.5% | 1.5% | ||
| Q1 25 | 0.8% | 1.0% | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 1.3% | 1.2% | ||
| Q2 24 | 1.7% | 1.4% | ||
| Q1 24 | 2.0% | 3.0% |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 4.36× | — | ||
| Q1 25 | 3.92× | — | ||
| Q4 24 | 4.11× | — | ||
| Q3 24 | 5.75× | — | ||
| Q2 24 | 7.13× | — | ||
| Q1 24 | 1.33× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNT
| Industrial And Electronics | $69.5M | 48% |
| Vehicle | $25.7M | 18% |
| Other | $20.9M | 15% |
| Aerospace And Defense | $20.6M | 14% |
| Distribution And Other Target Market | $6.7M | 5% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
